Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common and associated with significant morbidity and mortality due to its potential progression to cirrhosis and liver cancer. Whereas hepatic fat accumulation is the key to MASLD progression, little is known regard...

Descripción completa

Detalles Bibliográficos
Autores: Cervera, Marta, Pérez-Guasch, Martina, Carol, Marta, Nadal, Ruth, Sanz-Rodríguez, María, Juanola Mayos, Adrià, Soria, Anna, Hernández, Rosario, Sáez, Gemma, Pellón, Míriam, Herms, Queralt, Pose Méndez, Elisa, Ginès, Pere, Graupera, Isabel, Fabrellas i Padrès, Núria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/225934
Acceso en línea:https://hdl.handle.net/2445/225934
Access Level:acceso abierto
Palabra clave:Malalties del fetge
Metabolisme
Liver diseases
Metabolism
id ES_8dc6080b643b7b31dcf1211490f01fbc
oai_identifier_str oai:recercat.cat:2445/225934
network_acronym_str ES
network_name_str España
repository_id_str
spelling Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation ParameterCervera, MartaPérez-Guasch, MartinaCarol, MartaNadal, RuthSanz-Rodríguez, MaríaJuanola Mayos, AdriàSoria, AnnaHernández, RosarioSáez, GemmaPellón, MíriamHerms, QueraltPose Méndez, ElisaGinès, PereGraupera, IsabelFabrellas i Padrès, NúriaMalalties del fetgeMetabolismeLiver diseasesMetabolismBackground: Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common and associated with significant morbidity and mortality due to its potential progression to cirrhosis and liver cancer. Whereas hepatic fat accumulation is the key to MASLD progression, little is known regarding changes in liver fat content over time in the general population. We aimed to investigate changes in liver fat in a longitudinal study of the general population. Methods: We conducted a longitudinal study involving 195 randomly selected individuals from the general population, evaluated at two time points, 5 years apart. Participants with hepatic steatosis at baseline did not receive any specific treatment. The primary objective was to assess changes in liver fat content, as estimated by controlled attenuation parameter (CAP) using transient elastography. We also examined the frequency of steatosis resolution and development. CAP variability was assessed in two measurements 7 days apart in a cross-sectional study of 101 volunteers, with a mean variability of 9.9%. Steatosis resolution was defined as reduction of CAP > 10% from baseline with a final value < 275 dB/m, while steatosis development was defined as increase in CAP > 10% with a final value ≥ 275 dB/m. Results: Remarkable variations in liver fat content were observed. Among the 88 participants with steatosis at baseline, 34% had resolution of steatosis (CAP decreased from 300 to 237 dB/m; p < 0.001). Resolution was associated with weight loss and reductions in transaminases and gamma-glutamyl transferase levels. In contrast, 29% of the 107 participants without steatosis at baseline developed it during follow-up. Increase in liver stiffness measurement (≥ 8 kPa) was associated only with persistent hepatic steatosis but not with steatosis resolution. Conclusions: There is marked variation in liver fat content among participants from the general population over a period of 5 years, indicating its dynamic nature. These variations should be considered in epidemiological studies of MASLD.SAGE Publications2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfhttps://hdl.handle.net/2445/225934Articles publicats en revistes (Medicina)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1002/ueg2.70099United European Gastroenterology Journal, 2025, vol. 13, num.10, p. 1946-1954https://doi.org/10.1002/ueg2.70099cc by-nc-nd (c) Cervera, Marta et al., 2025https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2259342026-05-29T05:05:01Z
dc.title.none.fl_str_mv Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
title Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
spellingShingle Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
Cervera, Marta
Malalties del fetge
Metabolisme
Liver diseases
Metabolism
title_short Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
title_full Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
title_fullStr Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
title_full_unstemmed Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
title_sort Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter
dc.creator.none.fl_str_mv Cervera, Marta
Pérez-Guasch, Martina
Carol, Marta
Nadal, Ruth
Sanz-Rodríguez, María
Juanola Mayos, Adrià
Soria, Anna
Hernández, Rosario
Sáez, Gemma
Pellón, Míriam
Herms, Queralt
Pose Méndez, Elisa
Ginès, Pere
Graupera, Isabel
Fabrellas i Padrès, Núria
author Cervera, Marta
author_facet Cervera, Marta
Pérez-Guasch, Martina
Carol, Marta
Nadal, Ruth
Sanz-Rodríguez, María
Juanola Mayos, Adrià
Soria, Anna
Hernández, Rosario
Sáez, Gemma
Pellón, Míriam
Herms, Queralt
Pose Méndez, Elisa
Ginès, Pere
Graupera, Isabel
Fabrellas i Padrès, Núria
author_role author
author2 Pérez-Guasch, Martina
Carol, Marta
Nadal, Ruth
Sanz-Rodríguez, María
Juanola Mayos, Adrià
Soria, Anna
Hernández, Rosario
Sáez, Gemma
Pellón, Míriam
Herms, Queralt
Pose Méndez, Elisa
Ginès, Pere
Graupera, Isabel
Fabrellas i Padrès, Núria
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties del fetge
Metabolisme
Liver diseases
Metabolism
topic Malalties del fetge
Metabolisme
Liver diseases
Metabolism
description Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common and associated with significant morbidity and mortality due to its potential progression to cirrhosis and liver cancer. Whereas hepatic fat accumulation is the key to MASLD progression, little is known regarding changes in liver fat content over time in the general population. We aimed to investigate changes in liver fat in a longitudinal study of the general population. Methods: We conducted a longitudinal study involving 195 randomly selected individuals from the general population, evaluated at two time points, 5 years apart. Participants with hepatic steatosis at baseline did not receive any specific treatment. The primary objective was to assess changes in liver fat content, as estimated by controlled attenuation parameter (CAP) using transient elastography. We also examined the frequency of steatosis resolution and development. CAP variability was assessed in two measurements 7 days apart in a cross-sectional study of 101 volunteers, with a mean variability of 9.9%. Steatosis resolution was defined as reduction of CAP > 10% from baseline with a final value < 275 dB/m, while steatosis development was defined as increase in CAP > 10% with a final value ≥ 275 dB/m. Results: Remarkable variations in liver fat content were observed. Among the 88 participants with steatosis at baseline, 34% had resolution of steatosis (CAP decreased from 300 to 237 dB/m; p < 0.001). Resolution was associated with weight loss and reductions in transaminases and gamma-glutamyl transferase levels. In contrast, 29% of the 107 participants without steatosis at baseline developed it during follow-up. Increase in liver stiffness measurement (≥ 8 kPa) was associated only with persistent hepatic steatosis but not with steatosis resolution. Conclusions: There is marked variation in liver fat content among participants from the general population over a period of 5 years, indicating its dynamic nature. These variations should be considered in epidemiological studies of MASLD.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/225934
url https://hdl.handle.net/2445/225934
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1002/ueg2.70099
United European Gastroenterology Journal, 2025, vol. 13, num.10, p. 1946-1954
https://doi.org/10.1002/ueg2.70099
dc.rights.none.fl_str_mv cc by-nc-nd (c) Cervera, Marta et al., 2025
https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Cervera, Marta et al., 2025
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413073804066817
score 15,811543

Similares en LA Referencia